A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1<sup>+</sup> CLL cells
Amineh Ghaderi(Karolinska University Hospital), Mohammad Hojjat‐Farsangi(Karolinska University Hospital), Thomas Olin(Kancera (Sweden)), Layung Sekar Sih Wikanthi(Karolinska Institutet), Anders Österborg(Karolinska University Hospital), Håkan Mellstedt(Karolinska University Hospital), Marzia Palma(Karolinska University Hospital), Johan Schultz(Kancera (Sweden)), Mohammad Ali Okhovat(Karolinska University Hospital), Ann Svensson(University West)
Cited by 12
Related Papers
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2010|587
Nanoparticles and targeted drug delivery in cancer therapy
|Immunology Letters|2017|507
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer
|Biomedicine & Pharmacotherapy|2018|312